Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 2 Results

  1. 1
    139174

    Advances in battle against leishmaniasis.

    TDR NEWS. 1998 Oct; (57):2.

    The UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) has been concerned with the production of vaccines and drugs against leishmaniasis for a number of years. Weapons against the responsible parasite are slowly being improved. Recent reports from vaccine trials in Ecuador, Iran, and India have yielded encouraging results. In Ecuador, more than 70% of vaccinated children in one study were protected from cutaneous leishmaniasis (CL). The vaccine provided was given in 2 doses and consisted of whole killed Leishmania. In Iran, TDR supported the trial of a single dose vaccine in an area endemic for anthroponotic CL and with relatively low incidence, and another trial in an area endemic for zoonotic CL. The vaccines were comprised of whole killed L. major promastigotes together with BCG as adjuvant. 2 trials of vaccines given in single doses were supported by TDR. In a study in Bihar, India, aminosidine therapy yielded a 30-34% greater cure rate than did the standard regimen of pentostam. Aminosidine also had a low incidence of adverse reactions and was well tolerated.
    Add to my documents.
  2. 2
    107844

    Introduction.

    Godal T

    In: Tropical disease research: progress 1991-92. Eleventh programme report of the UNDP / World Bank / WHO Special Programme for Research and Training in Tropical Diseases (TDR). Geneva, Switzerland, World Health Organization [WHO], 1993. 1-14.

    1991 and 1992 were good years for the UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR). Major advances were made in controlling leprosy, onchocerciasis, and Chagas disease, using TDR-supported products; significant advances were made in applied field research, operational research, and in the social sciences; arteether was brought into fully controlled clinical trials and a field trial of a malaria vaccine in African children was initiated; an initiative was launched to control malaria through the genetic engineering of the mosquito vector to interrupt transmission; TDR's research capability strengthening (RCS) component accelerated its move toward strengthening through research and increased its focus upon identifying individuals for training as a first step in the RCS process; and TDR increased the level of convergence among its internal components and between TDR and other health programs, and prepared to define its targets in terms of precise products and time frames.
    Add to my documents.